Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Zydus Lifesciences's OCF Margin % or its related term are showing as below:
BOM:532321'
s OCF Margin % Range Over the Past 10 Years
Min: 7.92 Med: 15.12 Max: 30.04
Current: 7.92
During the past 13 years, the highest OCF Margin % of Zydus Lifesciences was 30.04%. The lowest was 7.92%. And the median was 15.12%.
BOM:532321's OCF Margin % is ranked worse than 54.57% of 962
companies
in the Drug Manufacturers industry
Industry Median: 10.035
vs BOM:532321: 7.92
Zydus Lifesciences OCF Margin % Related Terms
Zydus Lifesciences OCF Margin % Historical Data
* Premium members only.
The historical data trend for Zydus Lifesciences's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zydus Lifesciences OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Zydus Lifesciences's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zydus Lifesciences (BOM:532321) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Zydus Lifesciences and its competitors. Over the past decade, Zydus Lifesciences' OCF Margin % has ranged from 7.92 to 30.04. According to the industry distribution chart, Zydus Lifesciences ranks #525 out of 962 companies in the Drug Manufacturers industry, placing it in the top 54.6%.
Is Zydus Lifesciences' OCF Margin % too high?
Zydus Lifesciences' current OCF Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 7.92 to a high of 30.04. Based on the distribution chart, Zydus Lifesciences ranks #525 out of 962 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zydus Lifesciences has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zydus Lifesciences' OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Zydus Lifesciences ranks #525 out of 962 companies for OCF Margin %. This places Zydus Lifesciences in the lower half of its industry. The industry median OCF Margin % is 10.04. Historically, Zydus Lifesciences' own OCF Margin % has ranged from 7.92 to 30.04 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.04, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Zydus Lifesciences and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zydus Lifesciences's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zydus Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Zydus Lifesciences (BOM:532321) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,155.81, compared to a current price of ₹1,142.75 — trading 1.1% below its estimated fair value. The current OCF Margin % is 0.00%. Zydus Lifesciences' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Zydus Lifesciences (BOM:532321), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zydus Lifesciences (BOM:532321) Overvalued in 2026?
Based on GuruFocus' analysis, Zydus Lifesciences stock appears to be undervalued.
The current stock price of ₹1,142.75 is trading 1.1% below its estimated GF Value™ of ₹1,155.81.
GuruFocus considers Zydus Lifesciences to be Fairly Valued.
Key valuation signals for BOM:532321:
OCF Margin %: 0.00%
GF Value™: ₹1,155.81 vs. price of ₹1,142.75 (1.1% below fair value)
No single metric tells the full story. See the BOM:532321 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. It is engaged in the research, development, production, marketing, and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API), human formulations, animal health and veterinary, and consumer health and wellness products. Its products are marketed under brands like Amlodac, Inditel, Pivasta, and others. The company's operating segments are: Pharmaceuticals, which derives key revenue, and Consumer products. Geographically, it generates maximum revenue from the United States, followed by India, and other countries.
93GF Score
Get the complete analysis for BOM:532321
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532321 has been successfully added to your 
